Winstgevend schreef op 3 juni 2019 04:07:
21 mei 2019: First Berlin.
Source: Pharming Group NV
Meanwhile, we gather from talking to management that the time required to produce
sufficient stocks of a-glucosidase to begin the phase I/II trial in Pompe disease means that
this trial is likely to start towards the end rather than at the beginning of H1/20.
The phase I/II trial in pre-eclampsia, on the other hand, is expected to start “any day now”following approval from the relevant ethics committees.
Buy recommendation maintained at unchanged price target of €1.80 Although Q1/19
EBIT was above our forecast,
for the time being we are leaving our forecasts for the full year
2019 and subsequent years unchanged.
We maintain our Buy recommendation and price target of €1.80.
"Any day now" duurt inmiddels 14 dagen, kan niet ver meer weg zijn?
Laat die goedkeuring nu onderhand maar openbaar worden....